TITLE

TREATMENT WITH THE SELECTIVE COX-2 INHIBITOR ROFECOXIB IS ASSOCIATED WITH INCREASED ENDOTHELIAL CELL APOPTOSIS AND DECREASED VASCULARITY OF HUMAN COLORECTAL CANCER LIVER METASTASES

PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA119
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Treatment with the selective cyclooxygenase-2 inhibitor rofecoxib is associated with a 29 percent decrease in mean microvessel density in colorectal cancer (CRC) liver metastases compared with tumours from patients treated with placebo only. These data suggest that rofecoxib may have anti-angiogenic activity against CRC. This article cites a study to test the hypothesis that rofecoxib treatment is associated with increased endothelial cells (EC) apoptosis in human CRC liver metastases. Results of the study suggest that rofecoxib may induce apoptosis of EC leading to vessel regression and possible antiangiogenic activity in viva.
ACCESSION #
13219278

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics